PMID- 28831822
OWN - NLM
STAT- MEDLINE
DCOM- 20180801
LR  - 20181202
IS  - 1473-2300 (Electronic)
IS  - 0300-0605 (Print)
IS  - 0300-0605 (Linking)
VI  - 46
IP  - 1
DP  - 2018 Jan
TI  - Effect of zolpidem on functional recovery in a rat model of ischemic stroke.
PG  - 249-257
LID - 10.1177/0300060517723799 [doi]
AB  - Objective To evaluate the effects of zolpidem on functional recovery in a rat 
      model of acute ischemic stroke. Methods Following ischemic stroke procedures, 42 
      rats (six in each group) were randomly assigned to receive zolpidem (0.1, 0.25, 
      0.5, 1.0, 2.0 or 4.0 mg/kg) or normal saline administer intraperitoneally once 
      daily for two weeks. Motor behavioural index (MBI) scores, radial 8-arm maze 
      (RAM) test times and brain MRI scans were obtained 24 hours (Day 1) and two weeks 
      (Day 14) post-procedure. Immunohistochemistry was performed on Day 14. Results By 
      comparison with the normal saline group, the 0.5 and 1.0 mg/kg zolpidem groups 
      showed statistically significant improvements in MBI scores and increased numbers 
      of brain-derived neurotrophic factor (BDNF) stained cells over the two week 
      dosing period. By contrast, the 4.0 mg/kg zolpidem group had statistically 
      significantly impaired MBI scores compared with the control group. No differences 
      among groups were found in RAM times or infarction volumes. Conclusions This 
      study in a rat model showed that 0.5-1.0 mg/kg of zolpidem had beneficial effects 
      on behavioural recovery by enhancing neural plasticity without causing any memory 
      impairment in acute ischemic stroke.
FAU - Oh, Min-Kyun
AU  - Oh MK
AD  - 1 Department of Rehabilitation Medicine, Gyeongsang National University Changwon 
      Hospital, Gyeongsang National University School of Medicine, Changwon, Republic 
      of Korea.
FAU - Yoon, Kyung Jae
AU  - Yoon KJ
AD  - 2 Department of Physical & Rehabilitation Medicine, Kangbuk Samsung Hospital, 
      Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
AD  - 3 Medical Research Institute, Regenerative & Neuroscience laboratory, Kangbuk 
      Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of 
      Korea.
FAU - Lee, Yong-Taek
AU  - Lee YT
AD  - 2 Department of Physical & Rehabilitation Medicine, Kangbuk Samsung Hospital, 
      Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
AD  - 3 Medical Research Institute, Regenerative & Neuroscience laboratory, Kangbuk 
      Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of 
      Korea.
FAU - Chae, Seoung Wan
AU  - Chae SW
AD  - 4 Department of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University 
      School of Medicine, Seoul, Republic of Korea.
FAU - Choi, Hye Young
AU  - Choi HY
AD  - 5 Department of Radiology, Gyeongsang National University Hospital, Gyeongsang 
      National University School of Medicine, Jinju, Republic of Korea.
FAU - Shin, Hee Suk
AU  - Shin HS
AD  - 6 Department of Rehabilitation Medicine, Gyeongsang National University Hospital, 
      Gyeongsang National University School of Medicine, Jinju, Republic of Korea.
FAU - Park, Yun Hee
AU  - Park YH
AD  - 7 Department of Physical Medicine & Rehabilitation, Samsung Changwon Hospital, 
      Sungkyunkwan University School of Medicine, Changwon, Republic of Korea.
FAU - Chun, Se-Woong
AU  - Chun SW
AD  - 1 Department of Rehabilitation Medicine, Gyeongsang National University Changwon 
      Hospital, Gyeongsang National University School of Medicine, Changwon, Republic 
      of Korea.
FAU - Park, Young Sook
AU  - Park YS
AD  - 7 Department of Physical Medicine & Rehabilitation, Samsung Changwon Hospital, 
      Sungkyunkwan University School of Medicine, Changwon, Republic of Korea.
LA  - eng
PT  - Journal Article
DEP - 20170823
PL  - England
TA  - J Int Med Res
JT  - The Journal of international medical research
JID - 0346411
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (GABA-A Receptor Agonists)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Pyridines)
RN  - 7K383OQI23 (Zolpidem)
SB  - IM
MH  - Animals
MH  - Brain Ischemia/diagnostic imaging/*drug therapy/genetics/physiopathology
MH  - Brain-Derived Neurotrophic Factor/genetics/metabolism
MH  - Disease Models, Animal
MH  - Drug Administration Schedule
MH  - GABA-A Receptor Agonists/*pharmacology
MH  - Gene Expression
MH  - Injections, Intraperitoneal
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Maze Learning/drug effects
MH  - Neuroimaging/methods
MH  - Neuronal Plasticity/drug effects
MH  - Neuroprotective Agents/*pharmacology
MH  - Psychomotor Performance/drug effects
MH  - Pyridines/*pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Recovery of Function/*drug effects
MH  - Stroke/diagnostic imaging/*drug therapy/genetics/physiopathology
MH  - Zolpidem
PMC - PMC6011331
OTO - NOTNLM
OT  - Zolpidem
OT  - insomnia
OT  - ischemia
OT  - rat model of ischemic stroke
OT  - recovery
OT  - stroke
EDAT- 2017/08/24 06:00
MHDA- 2018/08/02 06:00
PMCR- 2018/01/01
CRDT- 2017/08/24 06:00
PHST- 2017/08/24 06:00 [pubmed]
PHST- 2018/08/02 06:00 [medline]
PHST- 2017/08/24 06:00 [entrez]
PHST- 2018/01/01 00:00 [pmc-release]
AID - 10.1177_0300060517723799 [pii]
AID - 10.1177/0300060517723799 [doi]
PST - ppublish
SO  - J Int Med Res. 2018 Jan;46(1):249-257. doi: 10.1177/0300060517723799. Epub 2017 
      Aug 23.